Now

What is currently held in attention.

Updated on a monthly cycle. A working record of what is being written, read, built, and weighed — not a press release.

TypeStanding recordCadenceMonthlyLast updated2026-05-10Next update2026-06-10AuthorAaron De Young

Currently being written.

The two questions to ask before adding any supplement.
In draft. Targeted to ship June 2026 alongside the Bio Stack Audit private beta.
What the Cochrane vitamin D review actually said.
Source review in progress. The article that motivated this site — the most cited and most misquoted review in the supplement literature.
Peptides and the gap between mechanism and evidence.
A long-form primer for adults considering peptide therapy. Outline complete. Reading the underlying trials.

Currently being read.

Outlive — Peter Attia
Reading critically. Several of his cardiovascular claims align well with the evidence; some of the longevity-drug positions are stronger than the current trial data supports. Notes accumulating for a piece on the gap.
Bad Pharma — Ben Goldacre
Re-reading sections on publication bias before approaching peptide-trial literature. Goldacre's framework holds up.
The Hallmarks of Aging — López-Otín et al. (Cell, 2023 update)
Standing reference for the longevity space. The 2023 expansion to twelve hallmarks is worth its own treatment.

Currently being built.

The Bio Stack Audit (private beta).
An interaction and confidence review for supplement and peptide stacks. In active development through Echelon Bio. Targeting private beta with an attorney-reviewed scope, not a public launch.
Author bench.
Quietly identifying two or three additional researchers and physicians whose register matches the editorial. Slow process; we will publish under names we trust.
Section illustrations.
Commission brief drafted. Looking for a single illustrator with editorial publication credits to draw three bronze-ink section markers in a consistent hand.

Currently being weighed.

Whether to publish a quarterly print companion.
Two of the reference publications we draw from (Monocle, Cereal) are print-first. The editorial register translates. Open question, no decision.
Whether to publish a sources-only newsletter.
Distinct from the waitlist. A short monthly digest of new entries to the Library plus revisions to existing positions. Subscribed to, not pushed.

This page exists because a publication is not a press release. A press release announces. A publication holds attention. Some of what is on this page will ship. Some of it will be quietly removed when the evidence does not hold up. That is the point.

Currently being written.

The two questions to ask before adding any supplement.

In draft. Targeted to ship June 2026 alongside the Bio Stack Audit private beta.

What the Cochrane vitamin D review actually said.

Source review in progress. The article that motivated this site — the most cited and most misquoted review in the supplement literature.

Peptides and the gap between mechanism and evidence.

A long-form primer for adults considering peptide therapy. Outline complete. Reading the underlying trials.

Currently being read.

Outlive — Peter Attia

Reading critically. Several of his cardiovascular claims align well with the evidence; some of the longevity-drug positions are stronger than the current trial data supports. Notes accumulating for a piece on the gap.

Bad Pharma — Ben Goldacre

Re-reading sections on publication bias before approaching peptide-trial literature. Goldacre's framework holds up.

The Hallmarks of Aging — López-Otín et al. (Cell, 2023 update)

Standing reference for the longevity space. The 2023 expansion to twelve hallmarks is worth its own treatment.

Currently being built.

The Bio Stack Audit (private beta).

An interaction and confidence review for supplement and peptide stacks. In active development through Echelon Bio. Targeting private beta with an attorney-reviewed scope, not a public launch.

Author bench.

Quietly identifying two or three additional researchers and physicians whose register matches the editorial. Slow process; we will publish under names we trust.

Section illustrations.

Commission brief drafted. Looking for a single illustrator with editorial publication credits to draw three bronze-ink section markers in a consistent hand.

Currently being weighed.

Whether to publish a quarterly print companion.

Two of the reference publications we draw from (Monocle, Cereal) are print-first. The editorial register translates. Open question, no decision.

Whether to publish a sources-only newsletter.

Distinct from the waitlist. A short monthly digest of new entries to the Library plus revisions to existing positions. Subscribed to, not pushed.